Haemonetics Elects Martin Madaus to Board of Directors
Haemonetics Corporation announced the election of Martin Madaus to its Board of Directors, effective July 24, 2026. Dr. Madaus brings over 30 years of leadership experience in the diagnostics and life sciences industries and will serve on the Audit Committee and Governance and Compliance Committee, receiving an annual equity award of approximately $200,000. Additionally, shareholders approved amendments to the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending its term through 2036, and the 2007 Employee Stock Purchase Plan, also extending its term through 2036. Shareholders also re-elected eight directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent auditor.
Key Highlights
- Martin Madaus was elected to Haemonetics' Board of Directors, effective July 24, 2026.
- Dr. Madaus will receive an annual equity award valued at approximately $200,000.
- Shareholders approved the Long-Term Incentive Plan, authorizing 4,680,000 additional shares.
- The Long-Term Incentive Plan and Employee Stock Purchase Plan terms were extended through 2036.
- Eight directors were re-elected for one-year terms at the annual meeting.
- Shareholders ratified Ernst & Young LLP as the independent auditor.
- Executive compensation was approved on an advisory basis.
- The annual meeting had a 92.53% quorum with 42,051,106 shares represented.
Price Impact
More from HAE